Other names FTY720, Gilenya
An immunomodulatory agent derived from ISP-1, a metabolite of Isaria sinclairii, a soil fungus and a structural analogue of sphingosine. It is phosphorylated* in vivo by sphingosine kinase 2 and FDA-approved to manage multiple sclerosis patients who don’t respond to interferon beta-1a. It reduces the MS relapse rate by 54% compared to untreated patients, and progression of disability by 30%.
Adverse effects Bradycardia, increased risk of serious infections, macular oedema, dyspnoea, hypertension, liver disease
*Once phosphorylated, fingolimod binds a sphingosine-1-phosphate receptor, S1PR1, sequestering lymphocytes, preventing their migration to the CNS, where they trigger an autoimmune reaction in patients with multiple sclerosis.
Reference Product literature, Novartis Pharma